Diversification
Acquisition
Novonesis case
SUCCESS & SYNERGY
Merger of the two
100

A company that sells smartphones starts selling smartwatches. Is this:

A. Related Diversification
B. Unrelated Diversification

a

100

True or False:

Acquisition is usually faster than internal development.

True

100

What is the new name of the merged company formed by Novozymes and Chr. Hansen?

Novonesis

100

What is a synergy?

When two companies together create more value than they could separately.

100

Before the merger, Novozymes was strong in industrial enzymes, while Chr. Hansen was strong in food cultures and probiotics.

In a post-merger SWOT analysis, which SWOT category is strengthened the most?

A. Weaknesses
B. Threats
C. Strengths
D. External Risks

C. Strengths

The merger combines complementary competencies and products, creating a stronger resource base. Novozymes was #1 in industrial enzymes, while Chr. Hansen was #1 in food cultures and dairy enzymes.

200

Which is the BEST example of unrelated diversification?

A. Nike buys a fitness app

B. Starbucks buys a coffee bean supplier

C. McDonald's buys an oil company

C

200

Complete the sentence:

Companies often acquire firms because it is faster and ______ uncertain than developing capabilities themselves.

Less uncertain

200

Which company was the global leader in industrial enzymes before the merger?

Novozymes (~48% market share)

200

Name one function where Novozymes and Chr. Hansen could create synergies.

  • R&D
  • Sales
  • Marketing
  • Manufacturing
  • IT
  • Sustainability
200

Name ONE market opportunity that both companies could pursue more effectively after the merger.

  • Sustainability solutions
  • Climate-neutral production
  • Food security
  • Growth in probiotics
  • Growth in microbial products
  • Growth in bioenergy
300

Why is internal development often difficult for diversification?

 Firms are path dependent.

300

Why did Tata Motors' share price initially fall after acquiring Jaguar Land Rover?

Investors worried about:

  • Debt
  • Acquisition costs
  • Integration risks
300

Chr. Hansen was the global leader in which products?

Food cultures and dairy enzymes.

300

Which grows faster according to the case?

A. Enzymes (~5% CAGR)

B. HMOs (~18% CAGR)

B. HMOs (~18% CAGR)

300

If you were the CEO, what would be the strongest strategic reason to merge Novozymes and Chr. Hansen?

A. Reduce competition only

B. Access complementary technologies and capabilities

C. Enter the oil industry

D. Diversify into unrelated businesses

B. Access complementary technologies and capabilities

Both companies operate in BioSolutions and have complementary expertise in enzymes, microbes, cultures, fermentation, and biotechnology.

400

Which diversification type generally has the highest chance of success?

A. Unrelated

B. Related Constrained

C. Related Linked

B

400

A company buys another company outside its industry. What major risk increases?

Integration and management risk

The acquirer may lack the knowledge and capabilities to run the new business.

400

Give ONE strategic reason why Novozymes and Chr. Hansen merged.

  • Complementary product portfolios
  • Shared biotechnology expertise
  • Sustainability opportunities
  • Growth in biosolutions markets
400

Based on diversification theory, what type of diversification best describes the Novozymes–Chr. Hansen merger?

Both Operational and Corporate Relatedness

  • Similar biotechnology knowledge
  • Similar R&D capabilities
  • Similar customers
  • Similar production technologies
  • Ability to share activities and transfer competencies

This is the highest-success quadrant.

400

How could the merger help reduce a weakness that each company might face by itself?

By combining resources, R&D capabilities, knowledge, patents, production facilities, and market access.

A larger company can spread costs, innovate faster, and compete more effectively with global rivals such as BASF and DuPont.

M
e
n
u